Management

Mr. Bersani has served as a member of our Board since June 2020. The Company appointed Mr. Bersani Chief Executive Officer effective May 10, 2022. From January 2022 to May 2022, Mr. Bersani served as interim Chief Executive Officer. From April 2020 to January 2022, Mr. Bersani was a Partner with B2B CFO Partners, LLC, which provides strategic management advisory services to owners of privately held companies. From November 2019 to March 2020, he served as the President, and Chief Executive Officer of K.P. Diamond Eagle, Inc., a consulting firm specialized in development of innovative commercial and private aviation business models. He served as a Senior Director within Alvarez & Marsal’s Private Equity Performance Improvement Practice, LLP between August 2018 and October 2019. From October 206 to July 2018, he served as President and Chief Executive Officer of K.P. Diamond Eagle, Inc. Prior to those professional experiences, Mr. Bersani served as the Chief Financial Officer of Fuel Systems Solutions, Inc. between April 2011 and October 2016.

Mr. Bersani is a Certified Public Accountant and is also a Certified Public Auditor and a Chartered Certified Accountant in Italy where he developed a significant knowledge of US GAAP and IFRS. Mr. Bersani earned a BA and MA in Business Economics from L. Bocconi University, Italy.
 

Leonardo “Leo” Mirandola, Ph.D. was named Chief Scientific Officer in July 2022, having served as the Company’s Vice President of Research & Development and Clinical Translation since September 2021. In May 2023, he was named Interim Chief Operations Officer. His previous roles were Head of Clinical Translation from 2020 to 2021, and Director of Clinical Operations from 2018 to 2019, having joined the Company in 2016 as Executive Director of Research and Development (R&D).

Dr. Mirandola is an expert in molecular immunology and immunotherapy research, having authored more than 100 publications including original research papers, abstracts, and book chapters. His studies have included, among other topics, breakthrough findings in the interactions between tumor cells and immune cells, primarily focusing on the tumor microenvironment, neoangiogenesis, cell signaling, and how they influence the development of new therapeutic strategies. Additionally, Dr. Mirandola is the inventor of nine different patent-pending technologies ranging from tumor biomarker identification and validation to cancer vaccines and adoptive cell therapies.

Before joining Kiromic, Dr. Mirandola was a post-doctoral research scientist at Texas Tech University Health Sciences Center.

He earned an M.S. in Medical Biotechnologies and a Ph.D. in Molecular Medicine at the University of Milan.